A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614).

Emily G Greengard,Robin Williams,Xiaowei Liu,Olga Militano,Terrence L. Fisher,Elizabeth E. Evans,Charles G. Minard,Joel M. Reid,Stephan D. Voss,Stacey L. Berg,Elizabeth Fox,Brenda J. Weigel

A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614).

2019

Emily G Greengard
Robin Williams
Xiaowei Liu
Olga Militano
Terrence L. Fisher
Elizabeth E. Evans
Charles G. Minard
Joel M. Reid
Stephan D. Voss
Stacey L. Berg
Elizabeth Fox
Brenda J. Weigel

e21519Background: Semaphorins regulate tumor progression, immune responses, and angiogenesis. SEMA4D was identified as a candidate proto-oncogene by a Sleeping Beauty forward genetic screen that in...

Keywords:

Refractory
Angiogenesis
Immune system
Oncology
Internal medicine
Young adult
Pathology
Genetic screen
Semaphorin
Tumor progression
Medicine
early adolescents

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations